📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-25 14:39
12 analysed today
FollowTelegram
12
Today
151,874
All-time analysed
43,544
Positive
6,743
Negative
92,750
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
KK Shah Hospitals FY26 Revenue at ₹9.43 Cr; Net Loss Widens to ₹0.62 Cr
KK Shah Hospitals' FY26 Annual Report reveals a marginal revenue growth of 4.8% to ₹9.43 Cr, while net losses nearly doubled to ₹0.62 Cr from ₹0.33 Cr in FY25. The company faces high fixed costs, with depreciation rising 66% to ₹1.68 Cr and professional fees paid to promoter-directors totaling ₹2.16 Cr. A key agenda for the upcoming AGM on August 18, 2026, is a special resolution to approve director remuneration exceeding statutory limits despite inadequate profits. The company remains loss-making with a negative ROCE of -5.5%.
Confidence: HIGH
What changedThe filing of the FY26 Annual Report confirms a widening of losses and highlights significant related-party payments to the promoter family.
Why it mattersFor a micro-cap company with a ₹26 Cr market cap, the high ratio of promoter remuneration to total revenue (~23%) and widening losses raise concerns about governance and path to profitability.
FY26 Revenue: ₹9.43 CrFY26 Net Loss: ₹0.62 CrPromoter Professional Fees: ₹2.16 CrFees vs FY26 Revenue: 22.9%AGM Date: 18th August 2026
📅 Short termThe stock may face pressure due to the reported widening of losses and high related-party expenses revealed in the full annual report.
📈 Long termThe long-term outlook remains challenging unless the company can significantly improve its operating margins and patient volumes to offset its fixed cost base.
⚠ Risk flags
- High related-party transactions (Promoter fees at 23% of revenue)
- Widening net losses
- Negative ROCE
- Micro-cap liquidity risk
Key Highlights
Revenue from operations increased slightly to ₹9.43 Cr in FY26 from ₹9.00 Cr in FY25.
Net loss widened significantly to ₹0.62 Cr compared to a loss of ₹0.33 Cr in the previous year.
Professional fees paid to four promoter-directors (Amit, Kirti, Hansa, and Milli Shah) totaled ₹2.16 Cr.
Depreciation and amortization expenses surged by 66% YoY to ₹1.68 Cr.
Company seeking shareholder approval for FY27 managerial remuneration exceeding 11% of net profits.
👀 What to Watch
Investors should monitor the voting results of the AGM regarding the special resolution for director remuneration and observe if the company can scale its operations to cover high fixed costs and promoter payouts.
